| 前收市價 | 0.1200 |
| 開市 | 0.3000 |
| 買盤 | 0.0500 |
| 賣出價 | 0.5500 |
| 拍板 | 7.50 |
| 到期日 | 2024-10-18 |
| 今日波幅 | 0.3000 - 0.3000 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 51 |
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
- Zacks
Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
Zentalis' (ZNTL) three studies evaluating azenosertib for three different cancer indications face the FDA's partial clinical hold following the death of two patients.
ZacksWall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
The consensus price target hints at a 136.4% upside potential for Zentalis Pharmaceuticals, Inc. (ZNTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
